Renal mesenchymal tumors were induced at high incidence in F344 rats by a single intraperitoneal injection of methyl(methoxymethyl)nitrosamine (DMN-OMe) within 48 h after birth. DNAs from 18 of 35 mesenchymal tumors contained transforming ras sequences in NIH3T3 transfection assays: K-ras (17/18) or N-ras (1/18). Singlestranded conforniational polymorphism analysis or dideoxy sequencing of polymerase chain reaction-amplified K-ras gene fragments revealed that these neoplasms contained a variety of activating mutations in the K-ras oncogene. Alterations in codon 12 predominated and included GGT -> GAT transitions, GGT -> GTT or TGT transversions, and previously reported insertion mutations, although some tumors expressed more than one mutation and the pattern of mutations even varied within tumors. Mutations were also found in exons 2 and 3. In addition, tumor transplantability into syngeneic hosts correlated positively and significantly with K-ras activation. Renal mesenchymal tumors with transforming mutations in exon 1 were often successfully passaged (10/12) while tumors which lacked mutations in exon 1 were infrequently transplantable (2/14). While the observed base substitutions in K-ras are consistent with adduct formation, the presence of insertion mutations and intratumor heterogeneity of alterations suggest that ras activation in DMN-OMe-induced tumors is not necessarily an early event in tumorigenesis.
methylguanine adducts following interaction of the carcinogen with DNA (6, 7) , suggesting that activation of K-ras may function in initiating tumorigenesis.
Previously, we reported the presence of transforming K-ras sequences in a large percentage of rat renal mesenchymal tumors induced by methyl(methoxymethyl)nitrosamine (DMNOMe; 8), a methylating agent presumed to behave much like AMMN in vivo. Ohgaki et al. (9) subsequently described the exclusive occurrence of GGT -» GAT 12 mutations in K-ras in paraffin-embedded sections from /V-nitrosodimethylamine (NDMA)-induced renal mesenchymal tumors and at a frequency of nearly twice that which we had reported earlier for DMN-OMe. We have now found that DMN-OMe-initiated tumors contain a variety of mutations in the K-ras gene and that the pattern of mutations may vary even within a tumor. We also describe results from transplantation studies that suggest that ras activation significantly enhances the malignant behavior of these tumors.
Within 48 h after birth, 39 male and 32 female F344/NCr rats (Animal Production Area, Frederick Cancer Research Facility) were given a single i.p. injection of DMN-OMe (4.0 mmol/kg body wt) as previously described (8) . Of 54 survivors, 39 animals eventually developed a renal tumor, of which 35 were confirmed by histology to be mesenchymal tumors using criteria previously described (10) . Tumors appeared with a mean latency of 35 weeks and were quick frozen on dry ice and stored at -70°C or processed for histology. Mesenchymal tumors frequently contained foci of blastemal-like cells, but consistently lacked a tumorigenic epithelial component characteristic of nephroblastomas. Tumor cells were highly invasive in the renal parenchyma, but were not observed to metastasize. Four cortical epithelial tumors that also occurred in this protocol were typical of tumors induced in adult rats (11) .
For transfection, assays were performed as described by Pulciani et al. (12) . Preliminary results from transfection studies of some of these tumors were reported previously (8) . Of 35 mesenchymal tumors assayed for transforming activity, DNA preparations from 18 tumors transformed NIH3T3 cells. Preparations from none of the four renal epithelial tumors induced transformation in NIH3T3 cells. Blotted DNAs were incubated with probes specific for K-ras, H-ras or N-ras. Of the 18 tumors with transforming sequences, 17 contained ratspecific bands for activated K-ras and one showed an activated N-ras gene (data not shown).
For molecular analyses of K-ras, genomic sequences from renal tumor DNAs were amplified by the polymerase chain reaction (PCR): for exon 1, sense (S) primer, 5'-TGAAAAT-GACTGAATATAAACTTGT-3' and antisense (AS) primer, 5'-CTCTATTGTTGGATCATATTCGTCC-3'; for exon 2, S primer, 5'-TTCCTACAGGAAGCAAGTAG-3' and AS primer, 5'-CACAAAGAAAGCCCTCCCCA-3'; for exon 3, S primer, 5'-GTTTCTTCCCCAGAGAACAA-3' and AS primer, 5'-TCGTCAACACCTGTCTTGTC-3'. Reaction mixtures were K.G.Higinbotham el al. To establish the position and probable type of mutation in all tumors prior to sequencing, we applied non-isotopic singlestranded conformational polymorphism (SSCP) analysis, as described (13), to PCR products amplified from K-ras exons 1, 2 or 3 in purified DNAs from primary tumors and from transformant NIH3T3 cells. In Figure 1 , PCR products for K-ras from primary tumors contained readily distinguishable SSCP profiles relative to the wild-type rat pattern (lane R). Mutant bands were present in primary tumors but often underrepresented relative to the wild-type allele ( Figure 1A) . In other tumors ( Figure IB) , two distinctly different SSCPbanding patterns were evident and wild-type bands were often absent from the profiles of primary tumors (lanes with tumor numbers), showing the loss of wild-type allele for this locus in certain tumors. Each rumor-derived product is juxtaposed in the figures with an NTH3T3 transformant product (T), and in every case the mutant SSCP profiles were identical, i.e. the transformants carried the same mutation in K-ras as observed in the primary tumors. The rat PCR products in transformants were preferentially amplified with rat-specific primers [ Figure 1A , rat (R) and mouse (M)], eliminating problems with amplification of mouse products from exon 1. The SSCP findings were completely consistent and reproducible regardless of tissue source, i.e. primary tumor or transformant.
Tumor PCR products which showed no SSCP polymorphisms in exon 1 were also evaluated for mutations in exons 2 and 3. For exon 2 ( Figure 2A ), two tumors (#6229 and 6254) contained two distinct SSCP profiles which differ from the wild-type (R) products and which were also demonstrable in transformants derived from those tumor DNAs. Additionally, two other tumors (#6222 and 6234) exhibited similar polymorphisms in exon 3 ( Figure 2B ) and, again, their transformants expressed the same SSCP profiles. To identify the specific mutations associated with each SSCP polymorphism, PCR-amplified fragments from exons 1, 2 and 3 were sequenced according to the manufacturer's instructions for the Sequenase version 2.0 sequencing kit (US Biochemical Corp.) using end-labeled primers. The results are summarized in Table I . GGT -» GAT 12 transitions were found for SSCP profiles shown in Figure 1A (tumor #6235, Figure 3B ). In addition, GGT -» GTT 12 transversions were identified for tumors #6219 ( Figure 3C ) and 6220, while GGT -» TGT, 2 mutations were found for tumors #6227 ( Figure 3D ) and 6267. Unique SSCP profiles and multiple mutations in codons 12/ 13 were observed for tumors #6240 and 6268: a double mutation (GGTGGC -> GTTTGC; Figure 4B ) and a triple mutation in the same region (GGTGGC -> GTCGAC). We also previously described two tumors with insertion mutations, involving tandem repeats of codons 12 and 13: #6246, a 9 bp insertion and #6274, a 12 bp insertion (14) . In addition, two transforming mutations were observed in exon 2: one with a codon 61 mutation (CAA -> CAT; Figure 4D ) and the second with the previously reported alteration in codon 63 (15) . Finally, two tumors contained mutations in exon 3, both of which were AAG -* AACn 7 transversions (data not shown). All other PCR products from tumor preparations that did not contain transforming ras genes also did not have point mutations in exons 1-3. This included the four renal epithelial tumors.
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Many of the renal tumors derived in this protocol were of considerable size and provided multiple tumor samples/regions from the same primary mass for DNA extraction. This permitted a crude topographical evaluation of tumor heterogeneity for K-ras activation. In two tumors, different SSCP profiles were noted in different regions of the same tumor masses. In tumor #6225, three of six different regions from the same primary tumor contained only wild-type alleles for K-ras ( Figure 5A , lanes 1, 2 and 4), while one region contained a GAT, 2 polymorphism (lane 3) and two others contained TGT ]2 polymorphisms (lanes 5 and 6). Similarly, for tumor #6242, only wild-type alleles were present in five of seven different regions from the tumor while GAT| 2 ( Figure 5B , lanes 1-5) polymorphisms were detected in two different regions of the same tumor (lanes 6 and 7). In each case transformants yielded the same polymorphism as the primary tumor region from which it was derived, and SSCP results were independently confirmed by dideoxy sequencing. These data suggest that there is intratumor heterogeneity in K-ras activation in these neoplasms and that negative transfection or SSCP results for a single region within a tumor are not necessarily reflective of the status of the remainder of the tumor.
Earlier studies with these tumors indicated that a fraction of them could be transplanted into syngeneic animals by intradermal injection of minced tumor tissue. In the current study, transplantation was successful with 12/26 renal mesenchymal tumors, and these transplants resembled histologically the primary tumors from which they were derived in that mixed patterns of embryonal-like and sarcomatous regions were maintained in the transplants. At the molecular level, all 12 primary tumors retained transforming K-ras sequences despite transplantation (data not shown). There is a striking correlation between the identification of an activated K-ras sequence in exon 1 and the ability of the tumor to be transplanted. Ten of 12 tumors with mutations in exon 1 of K-ras could be passaged numerous times while only two of 14 tumors that lacked mutations in exon 1 were transplantable (P < 0.001 by Fisher's exact test). Of the six transfectionpositive tumors that were not transplantable, all six were small tumors from which multiple samples could not be prepared.
Our studies indicate that K-ras activation is frequently associated with renal mesenchymal tumor formation (18/35) in F344 rats following a single neonatal exposure to DMNOMe. The frequency of activation in our tumor DNA prepara- tions corresponds with that in our earlier study (8) . The variety of mutations observed with DMN-OMe contrasts with our other studies in which nickel/iron-induced rat renal mesenchymal tumors were found to contain only GGT -> GTT| 2 transversions in K-ras (16) and with studies of NDMA- (9) or MNU-induced (5) renal tumors, in which only GGT -> GAT 12 mutations were observed. In the present study, only a third of the tumors with activated K-ras contained a G -> A transition, a characteristic result of C^-methylguanine formation. This may reflect relatively inefficient alkylation by DMNOMe, compared with NDMA or MNU. We have found that DMN-OMe treatment of newborn rats results in O 6 -methylguanine formation in kidney DNA, but at levels about one-sixth those occurring after a comparable dose of NDMA (unpublished observations). In any event, methylating agents have been reported in various systems to produce several of the mutations described here (7, 17, 18) . G -> T transversions were also frequently found in these tumors, and they might occur as a result of depurination of A^-methylguanine lesions or possibly as a consequence of oxidative damage (16, 19) since nitrosamines can induce 8-oxodeoxyguanosine adduct formation (20).
Alternatively, the variety of mutations may reflect the genetic instability concomitant with a mutator phenotype such as defective repair or replication processes. Such a mechanism could account for the type, variety and multiplicity of mutations in ras (21) . For example, the presence in two tumors of our previously described insertions of tandem repeats (14) suggests a mechanism involving errors in replication, which are common in cases of microsatellite instability and associated with a mutator phenotype (22) .
In studies of K-ras activation in human cancers, tumors often exhibit a spectrum of mutations, although point mutations in codon 12 usually predominate. Lung tumors contain a distribution of mutations, including GAT, TGT, GTT and GCT in codon 12, and TGC and GAC in codon 13 (23) . Since these mutations were not detected in preneoplastic lesions, they are believed to represent late events in tumorigenesis. However, the fact that the same ras mutation is uniformly distributed throughout a tumor would suggest that occurrence of the alteration is closely linked to neoplastic conversion (24) . The spectrum of mutations in colorectal cancer is even more widespread, and mutations are thought to arise late in tumor formation as well. Most large adenomas (diameters >1 cm) contained ras mutations while only 9% of the smaller lesions showed similar ras mutations (25) . Furthermore, the more aggressive neoplasms preferentially contained multiple mutations (26) . This would suggest the presence of a heterogeneous tumor cell population and enhanced genetic instability in these tumors. Indeed, such heterogeneity has been observed in both mini-and microsatellite sequences, markers of genomic instability, in a study of gastro-intestinal cancers (27) , and there is growing evidence for an association between microsatellite instability and subsequent ras activation (28, 29) . Recently, intratumor heterogeneity for ras was also found using topographical analyses of sections from individual prostate carcinomas (30) . In some cases, activated ras sequences were detected in certain areas of the tumor while none were identified in other regions; however, in one case different mutations in ras were observed in different areas of the same tumor. In the renal mesenchymal tumors, there may also be intratumor heterogeneity for K-ras activation since different regions of what appeared grossly to be the same tumor, contained either no mutations by SSCP analysis or different point mutations in codon 12. While we have not demonstrated the monoclonality of tumor areas, the occurrence of multiple intersecting neoplasms in the kidney with this protocol would be highly unusual (31) . Thus, our results using a gross topographical analysis of the renal tumors are consistent with those of human prostate tumors and provide supportive evidence for the late involvement of ras in the formation of these specific neoplasms.
In the current study, tumors bearing mutations in codon 12 of K-ras were readily transplantable, unlike those which lacked similar mutations. This finding corresponds with the abbreviated latency noted for nickel/iron-induced renal mesenchymal tumors having activated K-ras compared with nickelinduced tumors having wild-type K-ras (16) and may reflect an enhanced aggressive nature of tumor cells with mutated ras. The influence of ras mutations on tumor transplantability has been demonstrated in studies of the human PA1 teratocarcinoma cell line in which cells become tumorigenic in nude mice only after a GGT -> GAT 12 mutation in the Nras locus was detectable (32) . Similarly, lymphoma cells, which were not invasive or metastatic, became so upon transfection with an activated H-ras gene, and the most tumorigenic contained the highest ras copy number (33) .
Contrary to our findings for renal mesenchymal tumors, the renal cortical epithelial tumors, though only four in number, contained neither transforming sequences nor mutations in K-ras. This differs from the report by Ohgaki et al. (9) in which 75% of NDMA-induced renal cortical epithelial tumors exhibited GAT )2 mutations, but corresponds with other studies of rat (34) or human (35) renal cell carcinomas, in which mutations were not detected. Therefore, despite the common mesodermal origin of both renal tumor types, the tumorigenic pathways appear to differ since there is activation of K-ras only in the mesenchymal tumors.
In conclusion, the agent DMN-OMe, which induces tumors with a variety of K-ras mutations, behaves quite differently in tumorigenesis than the similar methylating agents NDMA, AMMN or MNU, which apparently cause only GAT )2 transitions. The type of mutations and their apparent intratumor heterogeneity in DMN-OMe-induced neoplasms suggest that alterations in K-ras may not occur early in tumorigenesis.
